Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Can
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
| Merck & Co. (NYSE: MRK) | Delayed: 144.67 -3.69 (2.49%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $148.36 | 52 Week High | $65.46 | |||
| Open | $147.01 | 52 Week Low | $47.97 | |||
| Day High | $147.62 | P/E | 98.41 | |||
| Day Low | $143.47 | EPS | $1.47 | |||
| Volume | 8,894,309 | |||||
